With a proven ability to develop 3-dimensional protein structures of exceptional precision, SBI has a developed a powerful program for efficient, well focused, drug discovery. Converting the in silico hits to drug candidates relies upon a combination of SBI’s expertise in computer-aided drug design, medicinal chemistry, cell biology, biochemistry, enzymology, and pharmacology, coupled with experienced leadership and a strong track record of success.

SBI’s uses its DynaPharm^® and CombiLib^® in silico screening technologies to rapidly generate drug leads for pharmaceutical and biotech corporate partners. This process reduces the number of compounds which need to be synthesized and tested by 1,000-10,000 fold and technology is truly responsive to the flood of novel target sequences being elucidated by human and infectious-disease efforts in genomics. By incorporating both “real” compound collections as well as virtual chemistry libraries, SBI’s Drug Discovery Services effectively open up the full potential of combinatorial chemistry, and cut the costs of acquiring or synthesizing, characterizing, indexing, storing, retrieving and testing chemical compounds by a corresponding factor of a thousand or more.

Collaborations

Through collaborations, SBI’s corporate partners are provided with custom modeling services, identification of active sites of pharmaceutical relevance, in silico screening of public and proprietary libraries, chemical sourcing services through ChemNavigator, as well as assay development.